Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Sarcoma and Rare Cancers 2023 | Elucidating the first-line therapy approach for the managing ACC

Otilia Kimpel, MD, University of Wuerzburg, Würzburg, Germany, discusses the different combinatorial therapies for patients with advanced adrenocortical carcinoma (ACC), including etoposide, doxorubicin, cisplatin combined with mitotane (EDP-M), which is the current first-line therapy approach. Dr Kimpel also comments on the second- and third-line treatment options offered to patients if EDP-M chemotherapy fails, while also touching on the disappointing results that targeted and immunotherapy interventions have yielded thus far. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.